Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis

被引：18

作者：

Bilezikian J.P. ^{[1
]}

Rubin M.R. ^{[1
]}

机构：

[1] Department of Medicine, College of Physicians and Surgeons, New York, NY 10032

来源：

Current Osteoporosis Reports | 2006年 / 4卷 / 1期

关键词：

Osteoporosis; Vertebral Fracture; Bone Density; Bone Turnover; Alendronate;

D O I：

10.1007/s11914-006-0009-2

中图分类号：

学科分类号：

摘要：

In this paper, we focus upon the use of anabolic skeletal therapy for the treatment of postmenopausal and other forms of osteoporosis. The only anabolic skeletal agent currently available is a recombinant bioactive fragment of parathyroid hormone, PTH(1-34), known as teriparatide. The full length molecule, human PTH(1-84) is being investigated at this time as are other PTH molecules. Teriparatide improves bone quality by actions on bone turnover, bone density, bone size, and microarchitecture. In postmenopausal women with osteoporosis, teriparatide reduces the incidence for vertebral and nonvertebral fractures. In individuals who have been treated previously with an antiresorptive agent, the subsequent actions of teriparatide on bone density are delayed transiently if bone turnover is markedly suppressed. Combination therapy with teriparatide or PTH(1-84) and an antiresorptive does not appear, at this time, to offer advantages over the use of PTH or an antiresorptive alone. To maintain the gains in bone density with PTH, it is important to follow its use with an antiresorptive agent. Copyright © 2006 by Current Science Inc.

引用

页码：5 / 13

页数：8

共 59 条

[1]

Hauselmann H.J., Rizzoli R., A comprehensive review of treatments for postmenopausal osteoporosis, Osteoporos Int, 14, pp. 2-12, (2003)

[2]

Rosen C.J., Postmenopausal osteoporosis, N Engl J Med, 353, pp. 595-603, (2005)

[3]

Dempster D.W., Cosman F., Kurland E.S., Et al., Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study, J Bone Miner Res, 16, pp. 1846-1853, (2001)

[4]

Hodsman A.B., Bauer D.C., Dempster D.W., Et al., Parathyroid hormone and teriparatide for the treatment of osteoporosis

[5]

a review of the evidence and suggested guidelines for its use, Endocr Rev, 26, pp. 688-703, (2005)

[6]

Lindsay R., Silverman S.L., Cooper C., Et al., Risk of new vertebral fracture in the year following a fracture, JAMA, 285, pp. 320-323, (2001)

[7]

Neer R.M., Arnaud C.D., Zanchetta J.R., Et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, pp. 1434-1441, (2001)

[8]

Body J.J., Gaich G.A., Scheele W.H., Et al., A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis, J Clin Endocrinol Metab, 87, pp. 4528-4535, (2002)

[9]

Prince R., Sipos A., Hossain A., Et al., Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment, J Bone Miner Res, 20, pp. 1507-1513, (2005)

[10]

Gallagher J.C., Genant H.K., Crans G.G., Et al., Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures, J Clin Endocrinol Metab, 90, pp. 1583-1587, (2005)

← 1 2 3 4 5 6 →